Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a nasal oxygen device prevent dangerous dips in blood oxygen during endoscopy for COPD patients?

NCT ID NCT07791979

Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether high-flow nasal cannula (HFNC) oxygen can reduce the risk of hypoxemia, or low blood oxygen, during sedated gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD). COPD patients often have low oxygen reserves, making them prone to hypoxemia during sedation. The study enrolls 90 adults with COPD who are scheduled for elective gastroscopy or colonoscopy. Participants receive HFNC oxygen during the procedure, and researchers track the incidence of hypoxemia and other breathing complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High-flow nasal cannula oxygenation
What this could lead to
If it works, this could offer a safer way to perform sedated gastrointestinal endoscopy in people with COPD, reducing the risk of dangerously low oxygen levels during the procedure.
What could go wrong
This is an early-stage, single-arm study with no comparison group, so results may not be definitive. There is also a theoretical concern that high oxygen levels could worsen carbon dioxide retention in COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * Confirmed diagnosis of chronic obstructive pulmonary disease (COPD); * Scheduled for elective sedated gastroenteroscopy (gastroscopy, colonoscopy, or combined gastroscopy and colonoscopy); * Expected procedure duration ≤45 minutes; * Provision of written informed consent by the participant. Exclusion Criteria: * Patients with absolute contraindications to high-flow therapy, including but not limited to confirmed diagnosis of complete upper airway obstruction, basilar skull fracture or nasal bone fracture, pneumothorax, or pneumomediastinum.; * American Society of Anesthesiologists (ASA) Physical Status class ≥ IV; * Requirement for planned endotracheal intubation; * Existing tracheostomy; * Confirmed pregnancy or currently breastfeeding; * Known allergy to sedative agents such as propofol; * Current participation in another interventional clinical trial; * Any other condition deemed by the investigator to make the patient unsuitable for trial participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease disease esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD) Esophageal cancer Gastric cancer (diagnosis) Hypoxemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.